Jun 2026 (Q2 FY26) — Aug 7, 2026
ANI Pharmaceuticals Q2 FY26 — Record Revenues and Strong Cortrophin Growth
Read the full callANI Pharmaceuticals (ANIP) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ANI Pharmaceuticals earnings: last reported Fri, 7 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 266 | +25.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 15.2 | +8.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 24.7 | +189.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$72.56 +0.37% · +$0.27
Performance −23.5% 1Y
1Y: $94.79 on 17 Oct 2025 → $72.56. High $95.38 (21 Oct 2025), low $70.16 (14 Oct 2026).
- Previous close
- $72.29
- 52-week range
- $70.16 – $95.38
- One year
- −23.72%
Overview
- Symbol
- ANIP
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ANI Pharmaceuticals earnings calls (ANIP)
Financials
What the filings say
Net profit, year on year: +189% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 191 | 197 | 211 | 228 | 247 | 237 | 266 |
| Expenses | 169 | 195 | 171 | 197 | 192 | 212 | 199 | 226 |
| Operating profit | -21 | -4 | 26 | 14 | 36 | 35 | 39 | 40 |
| Operating margin | −13.8% | −2.3% | 13.3% | 6.6% | 15.9% | 14.1% | 16.4% | 15.2% |
| Profit before tax | -31 | -14 | 20 | 11 | 34 | 31 | 40 | 37 |
| Tax rate | 23.3% | 25.3% | 21.5% | 18.8% | 21.3% | 12.7% | 26.7% | 33.4% |
| Net profit | -24 | -10 | 16 | 9 | 27 | 27 | 29 | 25 |
| EPS ($ per share) | -1.27 | — | 0.70 | 0.37 | 1.19 | — | 1.31 | 1.09 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 11 | 18 | -5 | -48 | -97 | -80 | -100 | -23 |
| Total liabilities | 233 | 244 | 265 | 413 | 422 | 447 | 856 | 900 |
| Fixed assets | 38 | 41 | 41 | 53 | 43 | 45 | 57 | 62 |
| Total assets | 431 | 457 | 461 | 772 | 760 | 904 | 1,284 | 1,440 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 67 | 46 | 15 | 3 | -31 | 119 | 64 | 185 |
| Cash from investing | -27 | -28 | -68 | -105 | -16 | -19 | -405 | -34 |
| Cash from financing | -28 | 1 | -1 | 195 | -5 | 67 | 265 | -10 |
| Net cash flow | — | — | — | 92 | -52 | 168 | -76 | 141 |
| Capital expenditure | -6 | -7 | -6 | -3 | -9 | -9 | -16 | -14 |
| Free cash flow | 61 | 39 | 9 | 1 | -40 | 110 | 48 | 171 |
Insider filings
106 filings between Nov 12, 2025 and Oct 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$15.47M
49 sales by 12 insiders
69% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
- 38
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Lalwani Nikhil | — | $5.44M | Oct 15, 2026 |
| Walsh Patrick D | — | $2.32M | May 13, 2026 |
| CAREY STEPHEN P. | — | $1.99M | Sep 29, 2026 |
| Mutz Christopher | — | $1.64M | Mar 13, 2026 |
| Gassert Chad | — | $1.31M | Nov 13, 2025 |
| Davis Krista | — | $918.6K | Mar 9, 2026 |
| Gutwerg Ori | — | $621.4K | Aug 10, 2026 |
| Cook Meredith | — | $454.6K | Oct 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Lalwani Nikhil PRESIDENT & CEO | Sale 10b5-1 plan | 5,400 | $388.2K |
| Oct 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $36.8K |
| Sep 29, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 2,850 | $208.1K |
| Sep 15, 2026 | Lalwani Nikhil PRESIDENT & CEO | Sale 10b5-1 plan | 5,400 | $383.4K |
| Sep 14, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $35.4K |
| Sep 11, 2026 | Thoma Jeanne Director | Sale 10b5-1 plan | 1,000 | $71.5K |
| Aug 31, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 2,850 | $207.5K |
| Aug 25, 2026 | Lalwani Nikhil PRESIDENT & CEO | Sale 10b5-1 plan | 5,400 | $401.2K |
| Aug 19, 2026 | Gosebruch Henry O Director | Award | 6,662 | $0 |
| Aug 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $37.7K |
| Aug 10, 2026 | Gutwerg Ori SVP, GENERICS | Sale | 3,162 | $243.5K |
| Jul 29, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 2,850 | $231.9K |
| Jul 18, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Tax withheld | 2,466 | $195.3K |
| Jul 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $40.9K |
| Jul 2, 2026 | CAREY STEPHEN P. SVP & CFO | Option exercise 10b5-1 plan | 3,313 | $164.0K |
| Jul 2, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 3,313 | $284.9K |
| Jun 29, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 2,850 | $239.7K |
| Jun 12, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $41.0K |
| Jun 8, 2026 | HAUGHEY THOMAS Director | Sale 10b5-1 plan | 2,000 | $161.8K |
| Jun 5, 2026 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 plan | 3,312 | $265.0K |
| Jun 5, 2026 | CAREY STEPHEN P. SVP & CFO | Option exercise 10b5-1 plan | 3,312 | $164.0K |
| May 21, 2026 | Leonard Matthew J Director | Award | 4,357 | $0 |
| May 21, 2026 | Pera Antonio R Director | Award | 4,357 | $0 |
| May 21, 2026 | TANNENBAUM RENEE P Director | Award | 4,357 | $0 |
| May 21, 2026 | HAUGHEY THOMAS Director | Award 10b5-1 plan | 4,357 | $0 |
| May 21, 2026 | Thoma Jeanne Director | Award | 4,357 | $0 |
| May 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $39.1K |
| May 13, 2026 | Walsh Patrick D Director | Sale | 10,000 | $806.3K |
| May 12, 2026 | Gutwerg Ori SVP, GENERICS | Sale | 2,772 | $220.4K |
| May 12, 2026 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | 459 | $36.4K |
| May 11, 2026 | Walsh Patrick D Director | Sale | 3,973 | $320.8K |
| May 11, 2026 | Lalwani Nikhil PRESIDENT & CEO | Sale | 55,000 | $4.27M |
| Apr 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $39.0K |
| Mar 13, 2026 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 plan | 3,162 | $226.5K |
| Mar 13, 2026 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 plan | 500 | $36.3K |
| Mar 11, 2026 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | 4,772 | $357.5K |
| Mar 9, 2026 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 plan | 5,087 | $377.1K |
| Mar 9, 2026 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 plan | 3,602 | $267.2K |
| Mar 7, 2026 | Gutwerg Ori SVP, GENERICS | Tax withheld | 3,314 | $245.4K |
| Mar 7, 2026 | Lalwani Nikhil PRESIDENT & CEO | Tax withheld | 17,060 | $1.26M |
| Mar 7, 2026 | CAREY STEPHEN P. SVP & CFO | Tax withheld | 5,150 | $381.3K |
| Mar 7, 2026 | Mutz Christopher HEAD OF RARE DISEASE | Tax withheld 10b5-1 plan | 3,314 | $245.4K |
| Mar 6, 2026 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 plan | 1,485 | $111.4K |
| Mar 6, 2026 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 plan | 2,121 | $157.4K |
| Mar 5, 2026 | CAREY STEPHEN P. SVP & CFO | Sale | 3,312 | $249.8K |
| Mar 5, 2026 | CAREY STEPHEN P. SVP & CFO | Option exercise | 3,312 | $164.0K |
| Mar 5, 2026 | CAREY STEPHEN P. SVP & CFO | Sale | 4,000 | $302.2K |
| Mar 3, 2026 | Gutwerg Ori SVP, GENERICS | Sale | 2,060 | $157.6K |
| Mar 3, 2026 | Walsh Patrick D Director | Sale | 6,000 | $445.4K |
| Mar 2, 2026 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 plan | 417 | $30.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ANI PHARMACEUTICALS INC
Free account. Everything above stays public.
Write why you follow ANI PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading